Aster Capital Management DIFC Ltd Reduces Stake in iShares Biotechnology ETF $IBB

Aster Capital Management DIFC Ltd decreased its stake in shares of iShares Biotechnology ETF (NASDAQ:IBBFree Report) by 45.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 7,210 shares of the financial services provider’s stock after selling 6,000 shares during the period. Aster Capital Management DIFC Ltd’s holdings in iShares Biotechnology ETF were worth $1,217,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its holdings in iShares Biotechnology ETF by 46,806.0% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 46,906 shares of the financial services provider’s stock worth $7,927,000 after purchasing an additional 46,806 shares in the last quarter. Tudor Investment Corp ET AL purchased a new stake in iShares Biotechnology ETF during the 3rd quarter worth about $931,000. WorthPointe LLC purchased a new stake in iShares Biotechnology ETF during the 4th quarter worth about $1,424,000. Central Pacific Bank Trust Division lifted its holdings in iShares Biotechnology ETF by 296,500.0% during the 4th quarter. Central Pacific Bank Trust Division now owns 14,830 shares of the financial services provider’s stock worth $2,503,000 after purchasing an additional 14,825 shares in the last quarter. Finally, Brookstone Capital Management lifted its holdings in iShares Biotechnology ETF by 91.0% during the 4th quarter. Brookstone Capital Management now owns 12,035 shares of the financial services provider’s stock worth $2,031,000 after purchasing an additional 5,735 shares in the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of IBB opened at $172.17 on Tuesday. The stock’s 50-day simple moving average is $170.34 and its 200 day simple moving average is $170.66. iShares Biotechnology ETF has a 52-week low of $123.61 and a 52-week high of $179.64.

iShares Biotechnology ETF Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 18th. Shareholders of record on Monday, June 15th will be issued a $0.0238 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $0.10 annualized dividend and a dividend yield of 0.1%.

iShares Biotechnology ETF Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Articles

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBBFree Report).

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.